Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02930850 · ClinicalTrials.gov registry record · NA

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation

A NA study of Healthy and Anemia, sponsored by Masimo Corporation.

Completed
Registry status
NA
Development phase
447
Enrollment target
7
Study locations

NCT02930850 is a NA study of Healthy and Anemia that has completed, run by Masimo Corporation. The registered enrollment target is 447 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02930850, a NA study of Healthy and Anemia, has completed, sponsored by Masimo Corporation.

COMPLETED
Registry status
NA
Development phase
447 participants
Enrollment target
7
Study locations

Study Summary

The purpose study is to report on the accuracy of noninvasive hemoglobin (SpHb) as compared to hemoglobin measurements obtained from a laboratory hematology analyzer.

Interventions

  • DEVICE Rad-67 Pulse oximeter

Study Locations (7)

California

  • Site 4 - Burbank
  • Site 5 - Burbank
  • Site 2 - Irvine
  • Site 7 - Lake Forest
  • Site 3 - National City
  • Site 6 - Torrance

North Carolina

  • Site 1 - Charlotte

Trial Details

FieldValue
Enrollment Target 447 participants
Start Date 2016-09
Est. Completion 2016-10
Phase NA

Sponsor

Masimo Corporation

96 total trials

What the Registry Record Tells You About NCT02930850

The ClinicalTrials.gov registry entry for NCT02930850 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (31% lower). The listed sponsor is Masimo Corporation, which has 96 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Rad-67 Pulse oximeter is the first listed.

NCT02930850 reports 7 study locations spanning 2 distinct geographic areas - top geographies include California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02930850 about?

NCT02930850 is a clinical study titled "Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation". The purpose study is to report on the accuracy of noninvasive hemoglobin (SpHb) as compared to hemoglobin measurements obtained from a laboratory hematology analyzer.

What is the current status of trial NCT02930850?

This trial is currently completed. It is a NA study. The enrollment target is 447 participants. The study started on 2016-09. Estimated completion is 2016-10.

What conditions does trial NCT02930850 study?

This clinical trial studies the following conditions: Healthy, Anemia, Pediatric ALL.

What interventions are being tested in trial NCT02930850?

The interventions under investigation include: Rad-67 Pulse oximeter (DEVICE).

Who is sponsoring clinical trial NCT02930850?

This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02930850 being conducted?

This trial has 7 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.